Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 8/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.50 |
| ▸ | PARP1 | P09874 | 7/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17825029 | 0.91 | PRMT5 (0.55) | PRMT5WDR77PARP1SLC6A4 | |
| SCHEMBL17825106 | 0.88 | PRMT5 (0.53) | PRMT5WDR77PARP1SLC6A4 | |
| SCHEMBL17824639 | 0.87 | PRMT5 (0.52) | PRMT5WDR77PARP1SLC6A4 | |
| SCHEMBL17825365 | 0.78 | PARP1 (0.42) | PRMT5WDR77PARP1 | |
| SCHEMBL24469152 | 0.76 | CNR2 (0.38) | CNR1CNR2SLC6A4MAPK1 | |
| SCHEMBL17825064 | 0.75 | PRMT5 (0.59) | PRMT5WDR77PARP1 | |
| SCHEMBL29480940 | 0.75 | PRMT5 (0.59) | PRMT5WDR77PARP1 | |
| SCHEMBL23099033 | 0.75 | PRMT5 (0.59) | PRMT5WDR77PARP1 | |
| SCHEMBL23099036 | 0.75 | PRMT5 (0.59) | PRMT5WDR77PARP1 | |
| SCHEMBL4843082 | 0.73 | ENPP1 (0.47) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| EP-3230273-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | Cancer Research Technology Ltd (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092326-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | PRMT5 235/4885WDR77 4475/4885PARP1 8/4885 |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | PARG, PARP15, PARP12 | PRMT5 235/4885WDR77 4475/4885PARP1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.